EY Entrepreneur of the year-2013 FROST & SULLIVAN Best Practices-2013 Business today/YES bank Excellence Awards-2013

Eris
Eris Lifesciences Limited

Date: 29 July 2026

To **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To **National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai-400051
Security Code: 540596	**Symbol: ERIS**

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., JULY 29, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 read with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("**LODR**") we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., July 29, 2026, *inter alia*, duly approved and took on record the following:

➢ Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

In this regard, the following documents are enclosed:

- A copy of the said financial results along with Limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications).
- Details as per Regulation 52(4) of SEBI Listing Regulations.

➢ Re-appointment of M/s Kiran J. Mehta & Co., Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, are given in the Annexure.

The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 01:00 P.M.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Digitally signed by Milind Talegaonkar
Date: 2026.07.29 13:06:48 +05'30'

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493

Walker Chandiok & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Eris Lifesciences Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and joint venture (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 30 June 2026 pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial results of 6 subsidiaries included in the Statement, whose financial information reflects total revenues of ₹ 129.45 Crores, total net profit after tax of ₹ 16.09 Crores and total comprehensive income of ₹ 16.03 Crores for the quarter 30 June 2026, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of ₹ 0.40 Crores and total comprehensive loss of ₹ 0.40 Crores for the quarter 30 June 2026, as considered in the Statement, in respect of 1 joint venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Ashish Gupta

Digitally signed by Ashish Gupta
Date: 2026.07.29 12:46:20 +05'30'

Ashish Gupta
Partner
Membership No.: 504662
UDIN: 26504662JZZRAM7487
Place: Mumbai
Date: 29 July 2026

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Annexure 1
List of entities included in the Statement

Sr. No.	Name of Entity	Relationship Type
1	Eris Lifesciences Limited	Holding Company
2	Eris Therapeutics Limited	Subsidiary
3	Aprica Healthcare Limited	Step-down Subsidiary
4	Eris Oaknet Healthcare Private Limited	Step-down Subsidiary
5	Eris Healthcare Private Limited	Subsidiary
6	Eris M. J. Biopharm Private Limited	Subsidiary
7	Eris Pharmaceuticals Limited (formerly Eris Pharmaceuticals Private Limited)	Subsidiary
8	Eris Bionxt Private Limited (formerly Chemman Labs Private Limited)	Subsidiary
9	Swiss Parenterals Limited	Subsidiary
10	Levim Lifetech Private Limited	Joint Venture

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026

[Rs in Crore except per share data]

Sr. No.	Particulars	For Quarter ended			For year ended
		June 30, 2026 (Unaudited)	March 31, 2026 (Refer Note 10)	June 30, 2025 (Unaudited)	March 31, 2026 (Audited)
1	**Income**				
	Revenue from operations				
	Sale of products	869.03	752.29	771.56	3,114.89
	Other operating income	4.22	4.27	1.44	14.53
	Total Revenue from operations	**873.25**	**756.56**	**773.00**	**3,129.42**
	Other income	2.39	2.23	2.69	7.75
	Total income	**875.64**	**758.79**	**775.69**	**3,137.17**
2	**Expenses**				
	Cost of materials consumed	94.27	68.12	70.10	326.65
	Purchase of stock-in-trade	131.12	122.97	104.26	490.56
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	13.86	(5.84)	10.28	(21.61)
	Employee benefits expense	153.42	136.85	144.43	556.81
	Finance costs	46.65	45.62	48.68	192.67
	Depreciation and amortisation expense	72.07	69.57	70.51	279.50
	Other expenses	184.36	160.89	167.22	656.90
	Total expenses	**695.75**	**598.18**	**615.48**	2,481.48
3	**Profit before share of profit from investment in joint venture, exceptional item and tax for the period / year (1-2)**	**179.89**	**160.61**	**160.21**	**655.69**
4	Share of loss/ (profit) from investment in joint venture, net of tax	0.40	1.20	(0.89)	(0.09)
5	**Profit before exceptional item and tax for the period / year (3-4)**	**179.49**	**159.41**	**161.10**	**655.78**
6	Exceptional items (Refer note 6)	-	-	-	17.24
7	**Profit before tax for the period / year (5-6)**	**179.49**	**159.41**	**161.10**	638.54
8	**Tax Expense**				
	Current tax	31.10	12.49	56.31	157.41
	Deferred tax (Refer note 7)	5.07	(132.18)	(20.31)	(166.38)
	Total tax expense	**36.17**	**(119.69)**	**36.00**	**(8.97)**
9	**Net profit for the period / year (7-8)**	**143.32**	**279.10**	**125.10**	647.51
	Attributable to :				
	- Owners of the Company	142.39	281.61	117.99	619.52
	- Non controlling interest	0.93	(2.51)	7.11	27.99
10	**Other comprehensive income/(loss)**				
	Items that will not be reclassified to gain or (loss)				
	Re-measurement gains / (losses) on defined benefit plans	0.16	2.64	(0.84)	0.12
	Income tax effect	(0.04)	(0.59)	0.27	0.22
	Items that will be reclassified to profit or loss				
	Net movement on effective portion of cash flow hedges	(0.03)	(2.21)	-	(2.42)
	Income tax effect	(0.03)	0.60	-	0.64
	Other comprehensive income/(loss) for the period / year, net of tax	**0.06**	**0.44**	**(0.57)**	**(1.44)**
	Attributable to :				
	- Owners of the Company	0.06	0.35	(0.56)	(1.47)
	- Non controlling interest	-	0.09	(0.01)	0.03
11	**Total comprehensive income**				
	Attributable to :				
	- Owners of the Company	142.45	281.96	117.43	618.05
	- Non controlling interest	0.93	(2.42)	7.10	28.02
	Total comprehensive income for the period / year (9+10)	**143.38**	**279.54**	**124.53**	**646.07**
12	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.86	13.85	13.62	13.85
13	Other Equity				3,888.82
14	Earnings Per Share (of Rs 1 each) (not annualised) :				
	Basic	10.28	20.60	8.66	45.33
	Diluted	10.26	20.57	8.64	45.26

WALKER CHANDIOK & Co. LLP CHARTERED ACCOUNTANTS

LIFESCIENCES LTD.

Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter ended June 30, 2026

Particulars	Quarter ended			For year ended
	June 30, 2026 (Unaudited)	March 31, 2026 (Refer Note 10)	June 30, 2025 (Unaudited)	March 31, 2026 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.64	0.61	0.74	0.61
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	2.75	3.95	2.60	2.91
Interest service coverage ratio (in times) (Earnings before share of profit from joint venture, exceptional items, Interest and Tax/Finance Costs)	4.86	4.52	4.29	4.40
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	3,944.22	3,895.66	3,399.10	3,895.66
Net profit after tax (Rs in crore)	143.32	279.10	125.10	647.51
Earnings per share				
Basic	10.28	20.60	8.66	45.33
Diluted	10.26	20.57	8.64	45.26
Current Ratio (in times) (Current Assets/Current Liabilities)	0.60	0.74	0.93	0.74
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity)	4.59	5.13	8.77	5.13
Bad debts to account receivable ratio (in times) (Bad debts/Trade receivables)	Nil	Nil	NIL	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.77	0.60	0.38	0.60
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.33	0.32	0.35	0.32
Debtors' turnover* (in times) (Sales/Trade receivables)	4.32	4.58	5.48	4.58
Inventory Turnover* (in times) (Cost of goods sold/Average Inventory)	1.93	2.06	2.41	2.06
Operating margin percent (Earnings before share of profit/ (loss) from joint venture, exceptional items, Finance cost and Tax/Revenue from Operations)	25.94%	27.26%	27.02%	27.11%
Net profit margin percent (Profit after tax/Revenue from Operations)	16.41%	36.89%	16.18%	20.69%

*Quarterly ratios based on trailing twelve months values.

WALKER CHANDIOK & Co LLP CHARTERED ACCOUNTANTS

ERIS LIFESCIENCES LTD

Notes to Unaudited Consolidated Financial results

1 The above statement of Unaudited Consolidated Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2026.

2 The Unaudited Consolidated Financial results of the Holding Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act") and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).

3 The Holding Company has issued and allotted 35,602 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the quarter ended June 30, 2026.

4 The Holding Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".

5 The Board of Directors of the Holding Company has declared an interim dividend of Rs 7.21/- (at the rate of 721 Percent) per equity share of the face value of Rs. 1/- each for the financial year 2026-27 at its meeting held on May 20, 2026.

6 Effective from November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Holding Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 17.24 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Holding Company has presented such incremental impact under "Exceptional Item" in the consolidated financial results for the year ended March 31, 2026.

7 In accordance with Ind AS 12 Income taxes, deferred tax assets and liabilities are measured using the tax rates that are enacted or substantively enacted through the Income tax Act 2025 as ammended by Finance Act 2026, as at the reporting date. Accordingly, during the quarter and year ended 31 March 2026, the Holding Company remeasured its deferred tax assets and liabilities based on the revised tax rate. This has resulted in an impact of deferred tax credit of Rs 150 Crores being recognized in the statement of profit and loss.

8 During the quarter and year ended March 31, 2026, the Holding Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Holding Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation.

9 During the year ended March 31, 2026, Eris Therapeutics Limited ("ETL") proposed the scheme whereby the "Domestic Business" of Eris Oaknet Healthcare Private Limited ("EOHPL") shall get vested into ETL ("Resulting Company/Amalgamated Company") and Aprica Healthcare Limited "AHL" ("Amalgamating Company") would be amalgamated with ETL. The respective Boards of Directors of ETL, AHL, and EOHPL have approved the Composite Scheme of Arrangement under Sections 230 to 232, read with Section 66 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to necessary statutory and regulatory approvals, as required under applicable laws.

10 The figures for the quarter ended March 31, 2026 as reported in these financial results are the balancing figures between the Audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the previous financial year which was subject to limited review.

For Eris Lifesciences Limited

WALKER CHANDIOK & CO. LLP CHARTERED ACCOUNTANTS

ERIS LIFESCIENCES LTD.

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: July 29, 2026

Walker Chandiok & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
“West Gate” Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement’) of ERIS Lifesciences Ltd (‘the Company’) for the quarter ended 30 June 2026 being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 (‘the Act’), other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and as per the presentation requirements of the SEBI Circulars, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Ashish Gupta

Digitally signed by Ashish Gupta
Date: 2026.07.29 12:47:25 +05'30'

Ashish Gupta
Partner
Membership No.: 504662
UDIN: 26504662OMKDDH2888
Place: Mumbai
Date: 29 July 2026

EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013

Business today/YES bank Excellence Awards-2013

Eris

Eris Lifesciences Limited

Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2026

Sr. No.	Particulars	For Quarter ended			For Year ended
		June 30, 2026 (Unaudited)	March 31, 2026 (Refer note 9)	June 30, 2025 (Unaudited)	March 31, 2026 (Audited)
					[Rs. in Crore except per share data]
1	**Income**				
	Revenue from Operations				
	Sale of products	433.81	267.52	567.90	1,779.77
	Other operating income	10.18	9.79	10.74	41.97
	Total Revenue from Operations	**443.99**	**277.31**	**578.64**	**1,821.74**
	Other Income	26.38	26.97	22.68	98.31
	Total Income	**470.37**	**304.28**	**601.32**	**1,920.05**
2	**Expenses**				
	Cost of materials consumed	19.99	22.53	24.12	83.99
	Purchase of stock-in-trade	128.10	122.95	106.69	478.22
	Changes in inventories of finished goods, stock-in-trade and work-in- progress	12.72	(7.72)	50.71	64.49
	Employee benefits expense	90.84	78.67	93.78	340.62
	Finance costs	42.16	42.70	45.14	179.54
	Depreciation and amortisation expense	39.98	38.82	37.60	154.38
	Other expenses	72.44	39.10	87.02	242.09
	Total expenses	**406.23**	**337.05**	**445.06**	**1,543.33**
3	**Profit/ (loss) before exceptional items and tax for the period / year(1-2)**	**64.14**	**(32.77)**	**156.26**	**376.72**
4	Exceptional items (Refer note 6)	-	-	-	14.67
5	**Profit/ (loss) before tax for the period / year (3-4)**	**64.14**	**(32.77)**	**156.26**	**362.05**
6	**Tax expense**				
	Current tax	10.23	(7.63)	27.17	60.96
	Deferred tax (Refer note 7)	5.61	(16.54)	29.10	57.04
	Total tax expense	**15.84**	**(24.17)**	**56.27**	**118.00**
7	**Net profit/ (loss) for the period / year (5-6)**	**48.30**	**(8.60)**	**99.99**	**244.05**
8	**Other Comprehensive income/ (loss)**				
	Items that will not be reclassified to profit or (loss)				
	Re-measurement gains / (losses) on defined benefit plans	0.16	2.96	(0.77)	0.65
	Income tax effect	(0.04)	(0.77)	0.27	0.04
	Other Comprehensive income/(loss) for the period / year, net of tax	**0.12**	**2.19**	**(0.50)**	**0.69**
9	**Total Comprehensive income/ (loss) for the period / year (7+8)**	**48.42**	**(6.41)**	**99.49**	**244.74**
10	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.86	13.85	13.62	13.85
11	Other Equity				3,181.61
12	Earnings/(Loss) Per Share (of Rs 1 each) (not annualised) :				
	Basic	3.49	(0.63)	7.34	17.86
	Diluted	3.48	(0.63)	7.33	17.83

WALKER CHANDIOK & Co LLP CHARTERED ACCOUNTANTS

LIFESCIENCES LTD.

Registered & Corporate Office:
Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter ended June 30, 2026

Particulars	Quarter ended			For Year ended
	June 30, 2026 (Unaudited)	March 31, 2026 (Refer note 9)	June 30, 2025 (Unaudited)	March 31, 2026 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.62	0.66	0.89	0.66
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	1.61	1.03	1.52	1.74
Interest service coverage ratio (in times) (Earnings before exceptional items, Interest and Tax/Finance Costs)	2.52	0.23	1.77	3.10
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	3,148.45	3,195.46	2,514.90	3,195.46
Net profit / (loss) after tax (Rs in crore)	48.30	(8.60)	30.47	244.05
Earnings/ (loss) per share				
Basic	3.49	(0.63)	7.34	17.86
Diluted	3.48	(0.63)	7.33	17.83
Current Ratio (in times) (Current Assets/Current Liabilities)	0.47	0.60	0.63	0.60
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets Current liabilities (excluding current maturity)	5.11	11.28	(14.23)	11.28
Bad debts to account receivable ratio (in times) (Bad debts/ Trade receivables)	Nil	Nil	Nil	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.91	0.67	0.37	0.67
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.36	0.36	0.43	0.36
Debtors' turnover* (in times) (Sales/ Trade receivables)	3.04	5.79	7.04	5.79
Inventory Turnover* (in times) (Cost of goods sold/Average Inventory)	5.29	4.01	3.53	4.01
Operating margin percent (Earnings before exceptional items, Interest and Tax/Revenue from Operations)	23.94%	3.58%	34.81%	30.53%
Net (loss)/profit margin percent ((Loss)/Profit after tax/Revenue from Operations)	10.88%	(3.10%)	17.28%	13.40%

*Quarterly ratios based on trailing twelve months values.

WALKER CHANDIOK & Co. LLP ★ CHARTERED ACCOUNTANTS ★

SCIENC LTD.

Notes to Unaudited Standalone Financial results

1 The above statement of Unaudited Standalone Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2026.

2 The Unaudited Standalone Financial results of the Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act") and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).

3 The Company has issued and allotted 35,602 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the quarter ended June 30, 2026.

4 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".

5 The Board of Directors of the Company has declared an interim dividend of Rs 7.21/- (at the rate of 721 Percent) per equity share of the face value of Rs. 1/- each for the financial year 2026-27 at its meeting held on May 20, 2026.

6 Effective from November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 14.67 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Company has presented such incremental impact under "Exceptional Item" in the standalone financial results for the year ended March 31, 2026.

7 In accordance with Ind AS 12 Income taxes, deferred tax assets and liabilities are measured using the tax rates that are enacted or substantively enacted through the Income tax Act 2025 as ammended by Finance Act 2026, as at the reporting date. Accordingly, during the quarter and year ended 31 March 2026, the Company remeasured its deferred tax assets and liabilities based on the revised tax rate applicable. This has resulted in an impact of deferred tax credit of Rs 18 Crores being recognized in the statement of profit and loss.

8 During the quarter and year ended March 31, 2026, the Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation.

9 The figures for the quarter ended March 31, 2026 as reported in these financial results are the balancing figures between the Audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the previous financial year which was subject to limited review.

For Eris Lifesciences Limited,

WALKER CHANDIOK & CO. LLP ★ CHARTERED ACCOUNTANTS ★

ERIS LIFESCIENCES LTD. ★

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: July 29, 2026

Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), senior management, Auditor and Compliance Officer:

Re-appointment of Cost Auditor:		
a)	Reason for Change viz., appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment.
b)	Date of re-appointment & term of re-appointment	The Board at its meeting held on July 29, 2026, approved the re-appointment of M/s Kiran J. Mehta & Co., Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27
c)	Brief profile	M/s. Kiran J Mehta & Co. is a partnership firm of Cost Accountants, working since last more than four decades. It started in the year 1977 as a proprietorship concern by Late Shri Kirankumar J. Mehta. Since the year 1990, it became partnership firm and as on date it is the oldest partnership firm in the Gujarat region since 1990. The firm has several small, medium, and large scale and even multinational clients. The firm's expertise is into Cost and Management Accounting areas. The gamut of its assignments include System, Cost Audit, Internal Audit, Stock Valuations, Excise related Valuation etc. The firm has a highly qualified team of Cost Accountants and other Staff members. The firm has its head quarter at Ahmedabad.
d)	Disclosure of relationships between directors	Not Applicable